Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19877236 | 0.92 | FLT3 (0.40) | FLT3KDM4ENPC1RAB9AKIT | |
| SCHEMBL17469806 | 0.81 | MAP4K4 (0.45) | FLT3KDM4ENPC1RAB9AMAP4K4 | |
| SCHEMBL21103816 | 0.80 | KIT (0.47) | FLT3KITNTRK3 | |
| SCHEMBL19891639 | 0.77 | FLT3 (0.35) | FLT3KDM4ENPC1RAB9A | |
| SCHEMBL19891638 | 0.75 | FLT3 (0.44) | FLT3KDM4ENPC1RAB9AMAP4K4 | |
| SCHEMBL19006326 | 0.74 | FLT3 (0.35) | FLT3KDM4ENPC1RAB9AMAP4K4 | |
| SCHEMBL21103088 | 0.72 | HPGD (0.47) | FLT3KDM4ENPC1RAB9A | |
| SCHEMBL23573082 | 0.72 | FLT3 (0.39) | FLT3KITNTRK3MAP4K4 | |
| SCHEMBL23599921 | 0.70 | MEN1 (0.47) | — | |
| SCHEMBL19877238 | 0.70 | FLT3 (0.68) | FLT3KITNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084039-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4011882-B1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | PURDUE RESEARCH FOUNDATION (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3496717-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018035072-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | FLT3 3/4885KDM4E 93/4885NPC1 3761/4885 |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | MCL1, ABL1, FLT3 | FLT3 3/4885KDM4E 93/4885NPC1 3761/4885 |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | FLT3 3/4885KDM4E 93/4885NPC1 3761/4885 |
| US-20250084039-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | FLT3 3/4885KDM4E 93/4885NPC1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.